Rituximab in the treatment of non-Hodgkin’s lymphoma
Beate Hauptrock, Georg HessHematology/Oncology, Johannes Gutenberg-University, Mainz, GermanyAbstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL).  R...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e9b43300eff141579113ef98d7a86425 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e9b43300eff141579113ef98d7a86425 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e9b43300eff141579113ef98d7a864252021-12-02T03:53:17ZRituximab in the treatment of non-Hodgkin’s lymphoma1177-54751177-5491https://doaj.org/article/e9b43300eff141579113ef98d7a864252008-09-01T00:00:00Zhttp://www.dovepress.com/rituximab-in-the-treatment-of-non-hodgkinrsquos-lymphoma-a2315https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Beate Hauptrock, Georg HessHematology/Oncology, Johannes Gutenberg-University, Mainz, GermanyAbstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL).  Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents.Keywords: non-Hodgkin’s lymphoma, rituximab, monoclonal-antibody, targeted therapy Beate HauptrockGeorg HessDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 619-633 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Beate Hauptrock Georg Hess Rituximab in the treatment of non-Hodgkin’s lymphoma |
| description |
Beate Hauptrock, Georg HessHematology/Oncology, Johannes Gutenberg-University, Mainz, GermanyAbstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL).  Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents.Keywords: non-Hodgkin’s lymphoma, rituximab, monoclonal-antibody, targeted therapy |
| format |
article |
| author |
Beate Hauptrock Georg Hess |
| author_facet |
Beate Hauptrock Georg Hess |
| author_sort |
Beate Hauptrock |
| title |
Rituximab in the treatment of non-Hodgkin’s lymphoma |
| title_short |
Rituximab in the treatment of non-Hodgkin’s lymphoma |
| title_full |
Rituximab in the treatment of non-Hodgkin’s lymphoma |
| title_fullStr |
Rituximab in the treatment of non-Hodgkin’s lymphoma |
| title_full_unstemmed |
Rituximab in the treatment of non-Hodgkin’s lymphoma |
| title_sort |
rituximab in the treatment of non-hodgkin’s lymphoma |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/e9b43300eff141579113ef98d7a86425 |
| work_keys_str_mv |
AT beatehauptrock rituximabinthetreatmentofnonhodgkinamprsquoslymphoma AT georghess rituximabinthetreatmentofnonhodgkinamprsquoslymphoma |
| _version_ |
1718401585896226816 |